Learn More

Cardiovascular-Systems-Inc-Headquarters

Leading the way in the fight against arterial calcium

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary artery disease. Our primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications it presents for the millions who suffer from peripheral artery disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe and effective medical devices to help improve patient outcomes.

We have developed patented orbital atherectomy systems (OAS) technology for both peripheral and coronary commercial applications.

Our peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee and address many of the limitations associated with other treatment alternatives.

Our coronary product is a catheter-based platform designed to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application.


Vision

To treat the symptoms of cardiovascular disease as a barrier to living a full life by providing awareness, education and innovation.

Leading the way to help treat arterial calcium

Committed to getting people with PAD and CAD back to what matters

Collaborating with
leading experts

Timeline

First Patient Enrolled in ECLIPSE Trial

Largest Coronary Atherectomy Trial to Date to Study OAS vs. Conventional Angioplasty Prior to Drug-eluting Stent Implantation for the Treatment of Severely Calcified Lesions

COAST Study Enrollment Completed

Study to Support Approval of Coronary OAS Micro Crown in the U.S. and Japan

CONFIRM Study Published

Peripheral OAS Registry

CALCIUM 360º Study Published

Peripheral OAS Study in Below-the-Knee Lesions

ORBIT II Study Enrollment Completed

Pivotal Study for Coronary OAS Classic Crown Conducted in the U.S.

COMPLIANCE Study Enrollment Completed

Peripheral OAS Study in Above-the-Knee Lesions

ORBIT I Study Enrollment Completed

Feasibility Study for Coronary OAS Classic Crown Conducted in India


Discover the orbital atherectomy solution for arterial calcium


CSI can help improve outcomes for patients with peripheral artery disease (PAD) and coronary artery disease (CAD),4-6 Our Diamondback 360® Orbital Atherectomy Systems (OAS) apply an innovative mechanism of action to treat complex calcium for both disease states.

Our Coronary OAS is the only device specifically indicated for severe coronary calcium, Diamondback 360 reduces calcified plaque, enabling successful stent deployment to help optimize PCI outcomes.

The Peripheral OAS offers multiple access solutions through its low profile technology to help physicians remove calcified lesions from hip to heel.35

Come work with us

CSI offers an exciting culture and rewarding career opportunities. If you share our passion for innovative, real-world solutions with the goal of improving patient care and quality outcomes, then consider joining us. Review our open positions, complete an application, and learn how you can become part of the CSI team.

CSI is an EEO/AA company: Women, Minorities, the Disabled and Veterans are encouraged to apply. If you are a job seeker with a disability and require accessibility assistance or reasonable accommodation to apply for an open position, please contact the Recruiting Department at CSI, 1255 Old Hwy 8, New Brighton MN 55112 or call (651) 259-1600.

Patient Stories

Learn more about actual patients who were helped getting back to what matters after being treated with CSI’s orbital atherectomy products.